# Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer

> **NCT00783172** · PHASE1 · TERMINATED · sponsor: **Milton S. Hershey Medical Center** · enrollment: 4 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **BIOLOGICAL:** Opioid Growth Factor (OGF)

## Key facts

- **NCT ID:** NCT00783172
- **Lead sponsor:** Milton S. Hershey Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-01
- **Primary completion:** 2010-08
- **Final completion:** 2011-10
- **Target enrollment:** 4 (ACTUAL)
- **Why stopped:** Problems with IRB
- **Last updated:** 2018-09-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00783172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00783172, "Opioid Growth Factor (OGF) and Gemcitabine: Novel Treatment for Pancreatic Cancer". Retrieved via MORVS 2026-10-18 from https://api.morvs.ai/clinical/NCT00783172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*